Press Releases
Please view the latest press from Enzo Biochem, Inc.
| Date | Details |
| Wednesday May 20, 2020 | Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV- 2 IgG Antibody Under FDA’s Emergency Use Authorization |
| Tuesday May 12, 2020 | Enzo Announces Issuance of U.S. Patent for Methods of Producing Monoclonal Antibodies Against Osteoporosis Drug Target Sclerostin |
| Wednesday April 29, 2020 | Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19 |
| Thursday April 23, 2020 | Enzo Biochem Launches Proprietary COVID-19 Diagnostic Test Under FDA’s Emergency Use Authorization |
| Tuesday March 24, 2020 | Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long Island |
| Friday March 6, 2020 | Enzo Biochem’s Full Service Clinical Laboratory to Launch Coronavirus (COVID-19) Testing Services Next Week |
| Thursday March 5, 2020 | Enzo Biochem Reports Fiscal Second Quarter Results |
| Tuesday February 25, 2020 | Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting |
| Wednesday February 19, 2020 | Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1‑I in a Model of Lupus |
|
For further information, please refer to: Regulatory role of SphK1 in TLR 7/9 – dependent type I interferon response and autoimmunity https://faseb.onlinelibrary.wiley.com/doi/epdf/10.1096/fj.201902847R |
|
| Tuesday February 11, 2020 | Enzo Biochem Announces Significant Milestone with Approval of Proprietary GenFlex Platform |
| Tuesday January 28, 2020 | Enzo Biochem Proposes to Increase Size of Board and Will Appoint Additional Highly Qualified, Diverse Independent Director in Near Future |
| Monday January 13, 2020 | Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert |